Eli Lilly’s obesity drug Zepbound led to nearly 50 percent more weight loss than Novo Nordisk’s Wegovy in the first direct ...

Federal regulators have accepted Novo Nordisk’s application to produce a pill version of its injectable weight-loss ...

A global trial reveals tirzepatide helps people lose more weight faster than semaglutide. This breakthrough could change ...

Shares of Septerna SEPN surged 51% on May 14 after the company entered into an exclusive global collaboration and license ...

Novo Nordisk NVO announced a significant partnership with Septerna SEPN, a U.S.-based biotech company, valued at up to $2.2 billion, to tap the growing obesity treatment market. Following the ...